CN1505524A - 免疫增强剂 - Google Patents
免疫增强剂 Download PDFInfo
- Publication number
- CN1505524A CN1505524A CNA028089561A CN02808956A CN1505524A CN 1505524 A CN1505524 A CN 1505524A CN A028089561 A CNA028089561 A CN A028089561A CN 02808956 A CN02808956 A CN 02808956A CN 1505524 A CN1505524 A CN 1505524A
- Authority
- CN
- China
- Prior art keywords
- ultramicrosome
- beta glucan
- mushroom
- composition
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000091 immunopotentiator Effects 0.000 title abstract description 4
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims abstract description 171
- 229920002498 Beta-glucan Polymers 0.000 claims abstract description 166
- 239000000203 mixture Substances 0.000 claims abstract description 149
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims abstract description 105
- 239000000284 extract Substances 0.000 claims abstract description 92
- 238000000034 method Methods 0.000 claims abstract description 60
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 49
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 19
- 208000010643 digestive system disease Diseases 0.000 claims abstract description 19
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 14
- 239000003443 antiviral agent Substances 0.000 claims abstract description 13
- -1 antidiabetics Substances 0.000 claims abstract description 12
- 230000008569 process Effects 0.000 claims abstract description 7
- 230000002519 immonomodulatory effect Effects 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 66
- 239000007864 aqueous solution Substances 0.000 claims description 65
- 239000002245 particle Substances 0.000 claims description 50
- 206010028980 Neoplasm Diseases 0.000 claims description 45
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 44
- 201000010099 disease Diseases 0.000 claims description 39
- 239000003814 drug Substances 0.000 claims description 38
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 36
- 235000005911 diet Nutrition 0.000 claims description 33
- 230000037213 diet Effects 0.000 claims description 33
- 239000002270 dispersing agent Substances 0.000 claims description 33
- 239000003995 emulsifying agent Substances 0.000 claims description 31
- 238000002360 preparation method Methods 0.000 claims description 31
- 229960001438 immunostimulant agent Drugs 0.000 claims description 29
- 239000003022 immunostimulating agent Substances 0.000 claims description 29
- 230000003308 immunostimulating effect Effects 0.000 claims description 29
- 239000007788 liquid Substances 0.000 claims description 29
- 239000002955 immunomodulating agent Substances 0.000 claims description 25
- 229940121354 immunomodulator Drugs 0.000 claims description 25
- 230000002584 immunomodulator Effects 0.000 claims description 25
- 230000000968 intestinal effect Effects 0.000 claims description 21
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 18
- 206010010774 Constipation Diseases 0.000 claims description 18
- 206010012735 Diarrhoea Diseases 0.000 claims description 18
- 239000000787 lecithin Substances 0.000 claims description 18
- 235000010445 lecithin Nutrition 0.000 claims description 18
- 229940067606 lecithin Drugs 0.000 claims description 18
- 208000011580 syndromic disease Diseases 0.000 claims description 18
- 240000007440 Agaricus campestris Species 0.000 claims description 16
- 235000004570 Agaricus campestris Nutrition 0.000 claims description 16
- 230000000172 allergic effect Effects 0.000 claims description 15
- 208000010668 atopic eczema Diseases 0.000 claims description 15
- 238000003809 water extraction Methods 0.000 claims description 15
- 230000002924 anti-infective effect Effects 0.000 claims description 13
- 239000003472 antidiabetic agent Substances 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 13
- 229940124597 therapeutic agent Drugs 0.000 claims description 13
- 229940127003 anti-diabetic drug Drugs 0.000 claims description 12
- 238000012545 processing Methods 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 11
- 238000004945 emulsification Methods 0.000 claims description 10
- 238000005469 granulation Methods 0.000 claims description 8
- 230000003179 granulation Effects 0.000 claims description 8
- 206010012601 diabetes mellitus Diseases 0.000 claims description 7
- 239000004606 Fillers/Extenders Substances 0.000 claims description 5
- 241000233866 Fungi Species 0.000 claims description 5
- 230000002052 anaphylactic effect Effects 0.000 claims description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 4
- 230000004520 agglutination Effects 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 206010002198 Anaphylactic reaction Diseases 0.000 claims description 3
- 208000035143 Bacterial infection Diseases 0.000 claims description 3
- 208000036142 Viral infection Diseases 0.000 claims description 3
- 230000036783 anaphylactic response Effects 0.000 claims description 3
- 208000003455 anaphylaxis Diseases 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 3
- 230000009385 viral infection Effects 0.000 claims description 3
- 240000000599 Lentinula edodes Species 0.000 abstract description 87
- 239000004480 active ingredient Substances 0.000 abstract description 6
- 239000000843 powder Substances 0.000 abstract description 6
- 235000013305 food Nutrition 0.000 abstract description 4
- 230000003178 anti-diabetic effect Effects 0.000 abstract description 3
- 239000000043 antiallergic agent Substances 0.000 abstract 1
- 229960005475 antiinfective agent Drugs 0.000 abstract 1
- 239000004599 antimicrobial Substances 0.000 abstract 1
- 239000006286 aqueous extract Substances 0.000 abstract 1
- 230000002434 immunopotentiative effect Effects 0.000 abstract 1
- 235000001715 Lentinula edodes Nutrition 0.000 description 88
- 239000000047 product Substances 0.000 description 44
- 230000000694 effects Effects 0.000 description 31
- 239000000243 solution Substances 0.000 description 28
- 239000002552 dosage form Substances 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 17
- 239000004615 ingredient Substances 0.000 description 17
- 230000035755 proliferation Effects 0.000 description 14
- 235000013402 health food Nutrition 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 238000009826 distribution Methods 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 235000013376 functional food Nutrition 0.000 description 11
- 230000036039 immunity Effects 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- 230000001900 immune effect Effects 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 210000004400 mucous membrane Anatomy 0.000 description 8
- 239000003085 diluting agent Substances 0.000 description 7
- 239000006185 dispersion Substances 0.000 description 7
- 230000000857 drug effect Effects 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 230000008595 infiltration Effects 0.000 description 7
- 238000001764 infiltration Methods 0.000 description 7
- 210000004347 intestinal mucosa Anatomy 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 5
- 201000004624 Dermatitis Diseases 0.000 description 5
- 208000006268 Sarcoma 180 Diseases 0.000 description 5
- 230000001804 emulsifying effect Effects 0.000 description 5
- 239000012467 final product Substances 0.000 description 5
- 230000036737 immune function Effects 0.000 description 5
- 230000007365 immunoregulation Effects 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- 206010003445 Ascites Diseases 0.000 description 4
- 206010070834 Sensitisation Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000003266 anti-allergic effect Effects 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000004957 immunoregulator effect Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000008313 sensitization Effects 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 230000003442 weekly effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- HJRJRUMKQCMYDL-UHFFFAOYSA-N 1-chloro-2,4,6-trinitrobenzene Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=C(Cl)C([N+]([O-])=O)=C1 HJRJRUMKQCMYDL-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 244000162269 Lentinus lepideus Species 0.000 description 2
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 108010013639 Peptidoglycan Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 240000001462 Pleurotus ostreatus Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 241000121220 Tricholoma matsutake Species 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000011218 segmentation Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241001327634 Agaricus blazei Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000221377 Auricularia Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000222356 Coriolus Species 0.000 description 1
- 241001492327 Crepidotus Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241001313734 Dictyophora Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000035874 Excoriation Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 240000006499 Flammulina velutipes Species 0.000 description 1
- 235000016640 Flammulina velutipes Nutrition 0.000 description 1
- 241000123326 Fomes Species 0.000 description 1
- 241001480537 Fomitopsis Species 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 241001149422 Ganoderma applanatum Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000222684 Grifola Species 0.000 description 1
- 240000001080 Grifola frondosa Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000218554 Lyophyllum Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000123526 Peziza Species 0.000 description 1
- 244000168667 Pholiota nameko Species 0.000 description 1
- 235000014528 Pholiota nameko Nutrition 0.000 description 1
- 241000743698 Pinicola Species 0.000 description 1
- 235000007685 Pleurotus columbinus Nutrition 0.000 description 1
- 235000001603 Pleurotus ostreatus Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 241000222480 Schizophyllum Species 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 241000123241 Sparassis Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229940043379 ammonium hydroxide Drugs 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- WJLUBOLDZCQZEV-UHFFFAOYSA-M hexadecyl(trimethyl)azanium;hydroxide Chemical compound [OH-].CCCCCCCCCCCCCCCC[N+](C)(C)C WJLUBOLDZCQZEV-UHFFFAOYSA-M 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002766 immunoenhancing effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940040371 lecithin 10 mg Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000003808 methanol extraction Methods 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/269—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of microbial origin, e.g. xanthan or dextran
- A23L29/271—Curdlan; beta-1-3 glucan; Polysaccharides produced by agrobacterium or alcaligenes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
- A23L31/10—Yeasts or derivatives thereof
- A23L31/15—Extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L21/00—Marmalades, jams, jellies or the like; Products from apiculture; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Dispersion Chemistry (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
Abstract
Description
施用组 | Day16 | |||
平均(g) | S.E. | t-检验 | M检验 | |
无处置组 | 2.493 | 0.246 | - | - |
仅乳化剂 | 2.817 | 0.401 | N.S. | N.S. |
香菇浸膏(10) | 1.844 | 0.363 | N.S. | N.S. |
香菇浸膏(100) | 2.712 | 0.522 | N.S. | N.S. |
胶束化香菇浸膏(10) | 1.507 | 0.1 63 | p<0.01 | p<0.01 |
胶束化香菇浸膏(100) | 1.744 | 0.394 | N.S. | N.S. |
施用组 | 肿瘤增殖抑制率(%) | ||
Day16* | |||
无处置组 | - | ||
仅乳化剂 | -13.0 | ||
香菇浸膏10) | 26.0 | ||
香菇浸膏(100) | -8.8 | ||
胶束化香菇浸膏(10) | 39.6 | ||
胶束化香菇浸膏(100) | 28.8 |
施用组 | Day16 | |||
平均(g) | S.E. | t-检验 | M检验 | |
无处置组 | 3.011 | 0.323 | - | - |
胶束化香菇浸膏(1) | 1.496 | 0.343 | p<0.01 | p<0.01 |
胶束化β-葡聚糖(1) | 1.468 | 0.256 | p<0.01 | p<0.01 |
β-葡聚糖(1) | 2.041 | 0.391 | N.S. | N.S. |
施用组 | 肿瘤增殖抑制率(%) | ||
Day16* | |||
无处置组 | - | ||
胶束化香菇浸膏(1) | 50.3 | ||
胶束化β-葡聚糖(1) | 51.2 | ||
β-葡聚糖(1) | 32.2 |
施用组 | 每根绒毛的单核细腻浸润的比例(%) | t-检验 | |
平均(%) | S.D. | ||
正常鼠*1 | 0.00 | 0.00 | - |
无处置组 | 0.31 | 0.27 | - |
仅乳化剂 | 0.24 | 0.41 | N.S. |
乳化剂+香菇提取浸膏(1)*2 | 0.35 | 0.60 | N.S. |
胶束化香菇浸膏(1) | 1.33 | 0.73 | p<0.1 |
胶束化香菇浸膏(3) | 1.34 | 0.08 | p<0.01 |
施用组 | 足肿(mm) | t-检验 | |
平均(mm) | S.D. | ||
正常鼠*1 | 0.08 | 0.05 | - |
无处置组 | 0.01 | 0.05 | - |
胶束化香菇浸膏(1) | 0.23 | 0.25 | p<0.05 |
β-葡聚糖溶液(1) | 0.08 | 0.11 | N.S. |
胶束化β-葡聚糖(1) | 0.17 | 0.08 | p<0.01 |
Claims (50)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP132513/2001 | 2001-04-27 | ||
JP2001132513 | 2001-04-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1505524A true CN1505524A (zh) | 2004-06-16 |
CN100391439C CN100391439C (zh) | 2008-06-04 |
Family
ID=18980516
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB028089561A Expired - Fee Related CN100391439C (zh) | 2001-04-27 | 2002-04-26 | 免疫增强剂 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20040142000A1 (zh) |
EP (1) | EP1389466B1 (zh) |
JP (1) | JP3633601B2 (zh) |
KR (3) | KR20040039195A (zh) |
CN (1) | CN100391439C (zh) |
AT (1) | ATE354355T1 (zh) |
DE (1) | DE60218299T2 (zh) |
TW (1) | TWI300714B (zh) |
WO (1) | WO2002087603A1 (zh) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102132864A (zh) * | 2011-02-22 | 2011-07-27 | 江苏安惠生物科技有限公司 | 诱导益生菌增殖的纳米食药用菌纤维及生产方法 |
CN101569414B (zh) * | 2008-04-29 | 2013-04-10 | 安琪酵母股份有限公司 | 一种富含酵母硒和酵母葡聚糖的组合物 |
CN103272214A (zh) * | 2013-05-30 | 2013-09-04 | 北京市农林科学院 | 金针菇蛋白质提取物及其抗肿瘤的应用 |
CN103272215A (zh) * | 2013-05-30 | 2013-09-04 | 北京市农林科学院 | 红平菇蛋白质提取物及其抗肿瘤的应用 |
CN106072533A (zh) * | 2016-06-18 | 2016-11-09 | 江苏阜丰生物科技有限公司 | 一种供糖尿病患者食用的全营养配方食品 |
CN106309511A (zh) * | 2016-08-30 | 2017-01-11 | 青海民族大学 | 圆孢蘑菇抑制cdc25酶有效部位及制法和应用 |
CN106333969A (zh) * | 2016-08-30 | 2017-01-18 | 青海民族大学 | 圆孢蘑菇抑制hdac1酶有效部位及制法和应用 |
CN115153023A (zh) * | 2014-07-02 | 2022-10-11 | 嘉康利公司 | 用于增强免疫的组合物和方法 |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7507724B2 (en) | 2001-01-16 | 2009-03-24 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
US7906492B2 (en) * | 2001-01-16 | 2011-03-15 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
NO20014256D0 (no) | 2001-09-03 | 2001-09-03 | Bjoern Kristiansen | Fremstilling av immunstimulerende forbindelse |
JP4808619B2 (ja) * | 2003-08-11 | 2011-11-02 | ルサフル、エ、コンパニ | 高血糖症の治療もしくは予防、または血糖の安定化に用いられる酵母細胞壁 |
KR20030086503A (ko) * | 2003-10-02 | 2003-11-10 | 신용달 | 말굽버섯 추출물을 응용한 기능성 항당뇨, 식음료제조방법과 그 제품 |
JP2005272405A (ja) * | 2004-03-26 | 2005-10-06 | Hokuto Corp | 皮膚機能改善剤及び皮膚機能改善食品 |
JP4863870B2 (ja) * | 2004-04-01 | 2012-01-25 | 株式会社クレハ | 抗アレルギー剤 |
JP2008509933A (ja) * | 2004-08-13 | 2008-04-03 | エミスフェアー・テクノロジーズ・インク | 送達剤のマイクロ粒子またはナノ粒子を含む医薬製剤 |
JP4560145B2 (ja) * | 2004-09-24 | 2010-10-13 | 株式会社 アンフィニ | 茸類の菌糸体加工方法 |
JP2006111820A (ja) * | 2004-10-18 | 2006-04-27 | Ajinomoto Co Inc | シイタケ子実体からのβ−グルカンの製造方法 |
KR100775133B1 (ko) * | 2005-04-06 | 2007-11-09 | 주식회사 한립생명공학 | 베타글루칸과 버섯 균사체 추출물을 혼합하여 제조한 항균 또는 항진균 제제의 제조방법 및 상기 제제를 함유하는 손발청결보습제 |
US20100086647A1 (en) * | 2005-05-13 | 2010-04-08 | Medimush As | Feed or food products comprising fungal material |
EP1896600A2 (en) | 2005-06-15 | 2008-03-12 | Medimush A/S | Anti-cancer combination treatment and kit-of-part |
WO2006137122A1 (ja) | 2005-06-20 | 2006-12-28 | Michio Tani | 抗エイズ剤 |
KR100734898B1 (ko) * | 2005-10-28 | 2007-07-03 | 주식회사 글루칸 | 베타-글루칸을 유효성분으로 포함하는 신장질환 치료용 약학적 조성물 |
US8323644B2 (en) * | 2006-01-17 | 2012-12-04 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
JP2007204717A (ja) * | 2006-02-06 | 2007-08-16 | Nagaoka Univ Of Technology | きのこ由来の多糖類取得方法 |
WO2007113835A1 (en) * | 2006-04-05 | 2007-10-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Anti-allergy compositions |
US20110129548A1 (en) * | 2006-10-20 | 2011-06-02 | Bioagra, Llc | Immunopotentiating Compositions Comprising Beta-1, 3/1, 6-D-Glucan and Uses Thereof |
US8586621B2 (en) * | 2006-10-27 | 2013-11-19 | Michael A. Zeligs | Anti-parasitic methods and compositions utilizing diindolylmethane-related indoles |
FR2918988B1 (fr) | 2007-07-20 | 2010-12-24 | Caster | Extrait polysaccharidique de lentinus et compositions pharmaceutiques, cosmetiques ou nutraceutiques comprenant un tel extrait. |
JP2011503161A (ja) * | 2007-11-13 | 2011-01-27 | バイオテック・ファルマコン・アーエスアー | 腸管の炎症性疾患を処置または予防する方法 |
CN101939411A (zh) * | 2008-02-06 | 2011-01-05 | 宝洁公司 | 用于提高呼吸病症免疫应答的组合物、方法和试剂盒 |
AU2009227183A1 (en) * | 2008-03-18 | 2009-09-24 | Amino Up Chemical Co., Ltd. | Enteral nutrient |
JP2010100576A (ja) * | 2008-10-24 | 2010-05-06 | Unitika Ltd | 便秘改善剤 |
KR20140128004A (ko) * | 2013-04-26 | 2014-11-05 | 한명순 | 송아지 설사 예방 및 개선용 조성물 및 그 제조방법 |
EP3102185B1 (en) | 2014-02-03 | 2021-07-14 | Apurano Pharmaceuticals GmbH | Nanosuspension of natural materials and preparation method thereof |
US10092609B2 (en) | 2015-01-16 | 2018-10-09 | James A. Wieser | Process for preparing medicinal mycological preparations |
KR101695186B1 (ko) * | 2016-02-05 | 2017-01-11 | 원광대학교산학협력단 | 당뇨병 예방, 개선 또는 치료용 조성물 |
JP7274863B2 (ja) * | 2016-09-30 | 2023-05-17 | 合同会社レビアスファーマ | 粒子およびその製造方法 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1356449A (en) * | 1970-12-30 | 1974-06-12 | Iizuka C | Process for extracting water soluble components of the hyphae of edible fungi |
DE3019614A1 (de) * | 1980-05-22 | 1981-12-03 | Sankyo Co., Ltd., Tokyo | Hydrolysiertes polysaccharid |
US4739046A (en) * | 1985-08-19 | 1988-04-19 | Luzio Nicholas R Di | Soluble phosphorylated glucan |
US5032401A (en) * | 1989-06-15 | 1991-07-16 | Alpha Beta Technology | Glucan drug delivery system and adjuvant |
CA2066172A1 (en) * | 1989-09-08 | 1991-03-09 | Alpha Beta Technology, Inc. | Method for producing soluble glucans |
CN1030038C (zh) * | 1991-03-07 | 1995-10-18 | 中国科学院石家庄农业现代化研究厅 | 以胡萝卜为药剂辅料的药剂制备方法 |
AUPN166195A0 (en) * | 1995-03-13 | 1995-04-06 | Norvet Research Pty Limited | Process for glucan extraction |
WO1997001330A1 (en) * | 1995-06-26 | 1997-01-16 | Research Triangle Pharmaceuticals | Novel adjuvant compositions and vaccine formulations comprising same |
JPH11262370A (ja) * | 1998-03-18 | 1999-09-28 | Nippon Shokukin Kogyo Kk | 健康食品素材としてのハラタケ科キノコの処理法および健康食品 |
EP1097715A4 (en) * | 1998-07-16 | 2004-12-29 | Hayashi Akira | PREPARATIONS FOR ANTICANCER IMMUNOTHERAPY COMPRISING A BACTERIAL SOMATIC COMPONENT AS AN ACTIVE INGREDIENT |
US6616928B1 (en) * | 1998-10-20 | 2003-09-09 | Yukiguni Maitake Co., Ltd. | Active oxygen scavenger and cancer chemopreventer from Grifola |
JP2000159682A (ja) * | 1998-09-17 | 2000-06-13 | Kozo Niwa | 生薬の抗腫瘍活性強化方法、抗腫瘍活性強化生薬含有組成物、生薬処理の抗腫瘍有効性評価方法、および生薬の抗腫瘍有効性評価方法 |
DE19911058B4 (de) * | 1999-03-12 | 2004-09-30 | Biotec Asa | Verwendung von nanoskaligen wasserlöslichen β-(1,3)-Glucanen |
JP3622595B2 (ja) * | 1999-10-15 | 2005-02-23 | 王子製紙株式会社 | 担子菌を含有する健康食品、飼料ならびにペットフード |
WO2002012348A2 (en) * | 2000-08-03 | 2002-02-14 | Abac R & D Gmbh | Isolation of glucan particles and uses thereof |
JP2004506689A (ja) * | 2000-08-18 | 2004-03-04 | アトラス ワールド ユーエスエー、インク. | 皮膚およびその他の障害の予防および治療のためにアガリクス・ブラゼイ・ムリルを使用すること |
US6645502B2 (en) * | 2001-09-17 | 2003-11-11 | Revlon Consumer Products Corporation | Anhydrous cosmetic compositions containing mushroom extract |
JP2006507239A (ja) * | 2002-08-13 | 2006-03-02 | バイオポリマー エンジニアリング,インコーポレイテッド | 放射線防護剤としてのベータグルカンの使用方法 |
-
2002
- 2002-04-26 WO PCT/JP2002/004205 patent/WO2002087603A1/ja active Application Filing
- 2002-04-26 KR KR10-2003-7013999A patent/KR20040039195A/ko not_active Application Discontinuation
- 2002-04-26 CN CNB028089561A patent/CN100391439C/zh not_active Expired - Fee Related
- 2002-04-26 KR KR1020097010648A patent/KR20090057480A/ko not_active Application Discontinuation
- 2002-04-26 JP JP2002584947A patent/JP3633601B2/ja not_active Expired - Lifetime
- 2002-04-26 AT AT02722816T patent/ATE354355T1/de not_active IP Right Cessation
- 2002-04-26 DE DE60218299T patent/DE60218299T2/de not_active Expired - Lifetime
- 2002-04-26 EP EP02722816A patent/EP1389466B1/en not_active Expired - Lifetime
- 2002-04-26 TW TW091108765A patent/TWI300714B/zh not_active IP Right Cessation
- 2002-04-26 KR KR1020107022055A patent/KR20100112205A/ko not_active Application Discontinuation
-
2003
- 2003-10-27 US US10/692,684 patent/US20040142000A1/en not_active Abandoned
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101569414B (zh) * | 2008-04-29 | 2013-04-10 | 安琪酵母股份有限公司 | 一种富含酵母硒和酵母葡聚糖的组合物 |
CN102132864A (zh) * | 2011-02-22 | 2011-07-27 | 江苏安惠生物科技有限公司 | 诱导益生菌增殖的纳米食药用菌纤维及生产方法 |
CN103272214A (zh) * | 2013-05-30 | 2013-09-04 | 北京市农林科学院 | 金针菇蛋白质提取物及其抗肿瘤的应用 |
CN103272215A (zh) * | 2013-05-30 | 2013-09-04 | 北京市农林科学院 | 红平菇蛋白质提取物及其抗肿瘤的应用 |
CN115153023A (zh) * | 2014-07-02 | 2022-10-11 | 嘉康利公司 | 用于增强免疫的组合物和方法 |
CN115153023B (zh) * | 2014-07-02 | 2024-06-04 | 嘉康利公司 | 用于增强免疫的组合物和方法 |
CN106072533A (zh) * | 2016-06-18 | 2016-11-09 | 江苏阜丰生物科技有限公司 | 一种供糖尿病患者食用的全营养配方食品 |
CN106309511A (zh) * | 2016-08-30 | 2017-01-11 | 青海民族大学 | 圆孢蘑菇抑制cdc25酶有效部位及制法和应用 |
CN106333969A (zh) * | 2016-08-30 | 2017-01-18 | 青海民族大学 | 圆孢蘑菇抑制hdac1酶有效部位及制法和应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2002087603A1 (fr) | 2002-11-07 |
EP1389466B1 (en) | 2007-02-21 |
EP1389466A4 (en) | 2004-09-22 |
EP1389466A1 (en) | 2004-02-18 |
JPWO2002087603A1 (ja) | 2004-08-12 |
US20040142000A1 (en) | 2004-07-22 |
DE60218299D1 (de) | 2007-04-05 |
CN100391439C (zh) | 2008-06-04 |
DE60218299T2 (de) | 2007-10-31 |
KR20090057480A (ko) | 2009-06-05 |
JP3633601B2 (ja) | 2005-03-30 |
ATE354355T1 (de) | 2007-03-15 |
TWI300714B (en) | 2008-09-11 |
KR20040039195A (ko) | 2004-05-10 |
KR20100112205A (ko) | 2010-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1505524A (zh) | 免疫增强剂 | |
CN1275604C (zh) | 用于白细胞活化和增殖的口服组合物 | |
CN1192098C (zh) | 樟芝菌丝体生物活性物质其制备法及含其组成物 | |
CN1668325A (zh) | 乳铁蛋白在治疗恶性肿瘤及其它过度增生性疾病中的用途 | |
CN1320121C (zh) | 制备蘑菇乳酸发酵溶液的方法及由此制备的蘑菇乳酸发酵溶液 | |
CN1255376A (zh) | 增强生药材抗肿瘤活性的方法 | |
CN1920049A (zh) | 小分子生物活性肽及其制法、组合物和应用 | |
CN1100561C (zh) | 编程性细胞死亡诱导剂 | |
CN1198639C (zh) | 新型免疫增强组合物 | |
CN1883527A (zh) | 一种灵芝保健品及其制备方法 | |
CN1927006A (zh) | 一种营养酵母食品及其制备方法 | |
CN1452973A (zh) | 一种抗氧化降血脂的口服药物 | |
CN1869208A (zh) | 虫草sod的制备以及含虫草sod的保健品 | |
JP4752233B2 (ja) | 免疫賦活剤 | |
CN1767837A (zh) | 用于免疫活性或防治癌症的包含从酿酒酵母is2中得到的可溶性葡聚糖低聚物的组合物及其制备方法 | |
CN100340186C (zh) | 姬松茸水溶性多糖及其制备工艺和用途 | |
CN1600147A (zh) | 一种糖肽复合物免疫强化饲料添加剂及其制备方法和用途 | |
CN100345538C (zh) | 含有蛇葡萄素和杨梅素的组合物在制备降血糖药物中的用途 | |
CN1546533A (zh) | 猴头菌硫酸酯蛋白多糖、其制备方法和以该化合物为活性成分的药物组合物 | |
CN100345539C (zh) | 含有二氢杨梅素和杨梅素的组合物 | |
CN1615743A (zh) | 复合大豆异黄酮保健片 | |
CN1537632A (zh) | 预防和治疗高血脂症的保健品 | |
CN1872120A (zh) | 一种保健品片剂及其制备和应用 | |
WO2022186042A1 (ja) | コレステロールの低減剤 | |
CN1809287A (zh) | 用于降低血糖指数的组合物和食品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160727 Address after: Tokyo, Japan, Japan Patentee after: EA pharmaceutical KK Address before: Japan Tokyo central Beijing a chome 15-1 Patentee before: Ajinomoto K. K. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20180130 Address after: Tokyo, Japan Patentee after: RL-JP Corporation Address before: Tokyo, Japan, Japan Patentee before: EA pharmaceutical KK |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080604 Termination date: 20210426 |
|
CF01 | Termination of patent right due to non-payment of annual fee |